Kantar Health Blog

  • The Landscape of Cancer: Immunotherapy Shining Through

    by Stephanie Hawthorne | Oct 7, 2015
    Stephanie Hawthorne
    Immunotherapy is shining through in the crowded space that is oncology, over 6,000 oncology drugs are in development with more than 2,400 different mechanisms of action (MOAs). Immunotherapies have started to enter the mainstream, with many headlines touting immunotherapy as the Holy Grail of cancer treatment.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ECC 2015 --- Without a doubt, PD-1 and PD-L1 inhibitors have taken the oncology field by storm. With its approval in Japan in July 2014 for unresectable melanoma, Opdivo® (nivolumab, Bristol-Myers Squibb/Ono Pharmaceuticals) was the first PD-1 inhibitor to be approved worldwide and represented the culmination of a longstanding quest to harness the body’s inherent immune system to combat cancer.
    Continue Reading > | Go comment! | Share
  • Bladder Cancer Treatment IMvigor-ated

    by Stephanie Hawthorne | Sep 28, 2015
    Stephanie Hawthorne
    Oncology Conference Insight: ECC 2015 --- Approximately 70% to 80% of patients with newly diagnosed bladder cancer will present with superficial or Stage I bladder tumors. Patients with these superficial tumors can often be cured, but those with muscle-invasive or metastatic disease are cured less often and are treated with surgery, irradiation or a combination of modalities that includes systemic therapy.
    Continue Reading > | Go comment! | Share
  • Crowd surfing: Competition in myeloma continues to rage on

    by Stephanie Hawthorne | Jun 2, 2015
    Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- The number of agents available to treat relapsed/refractory myeloma has expanded rapidly over the past three years, with the launch of next-generation proteasome inhibitor Kyprolis® (carfilzomib, Onyx /Amgen, accelerated FDA approval July 2012) and the next-generation immunomodulator Pomalyst® (pomalidomide, Celgene, FDA approved February 2013) as monotherapies, and the HDAC inhibitor Farydak® (panobinostat, Novartis, accelerated FDA approval February 2015) for use in combination with bortezomib + dexamethasone (VelDex). These three agents add to the long-established standards of care, Velcade® (bortezomib, Millennium/Takeda) and Revlimid® (lenalidomide, Celgene), which are used in both newly diagnosed and relapsed/refractory patients.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO 2015 --- In several B-cell malignancies, physicians have a number of new options for their patients, allowing these patients the promise of being treated for several lines of therapy. For chronic lymphocytic leukemia (CLL) and indolent lymphoma patients, physicians now have the option to use kinase inhibitors such as Imbruvica® (ibrutinib, Pharmacyclics/Janssen) or Zydelig® (idelalisib, Gilead). For multiple myeloma patients, physicians now have the option to utilize Kyprolis® (carfilzomib, Amgen/Onyx) or Pomalyst® (pomalidomide, Celgene).
    Continue Reading > | Go comment! | Share